NEOMYCIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Neomycin, and what generic alternatives are available?
Neomycin is a drug marketed by Pharmafair, Watson Labs, Xgen Pharms, Bausch And Lomb, Padagis Us, Saptalis Pharms, Alcon Pharms Ltd, Amring Pharms, Ipharm, Sandoz, Akorn, Bristol Myers Squibb, Chartwell Molecular, Lannett, Lilly, Nostrum Labs Inc, Roxane, Teva, Fougera, and Pharmaderm. and is included in forty-two NDAs.
The generic ingredient in NEOMYCIN is neomycin sulfate; triamcinolone acetonide. There are nineteen drug master file entries for this compound. Additional details are available on the neomycin sulfate; triamcinolone acetonide profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NEOMYCIN?
- What are the global sales for NEOMYCIN?
- What is Average Wholesale Price for NEOMYCIN?
Summary for NEOMYCIN
US Patents: | 0 |
Applicants: | 20 |
NDAs: | 42 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for NEOMYCIN |
DailyMed Link: | NEOMYCIN at DailyMed |
![NEOMYCIN drug patent expirations Drug patent expirations by year for NEOMYCIN](/p/graph/s/t/NEOMYCIN-patent-expirations.png)
![Drug Prices for NEOMYCIN](/p/graph/drug-price/NEOMYCIN.png)